Phio Pharmaceuticals Corp. (PHIO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Phio Pharmaceuticals Corp., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Phio Pharmaceuticals Corp. (PHIO) has returned 16.19% so far this year and -6.15% over the past 12 months. Over the last ten years, PHIO has returned -69.23% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since May 10, 2012, PHIO's average daily return is +0.08%, while the average monthly return is -5.38%.

Historically, 34% of months were positive and 66% were negative. The best month was Feb 2013 with a return of +100.0%, while the worst month was Feb 2020 at -68.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.

On a daily basis, PHIO closed higher 40% of trading days. The best single day was Jul 18, 2012 with a return of +806.2%, while the worst single day was Jul 9, 2012 at -88.9%.

Phio Pharmaceuticals Corp. has an annualized alpha of 7.13%, beta of 0.98, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 11, 2012.

• This stock participated in 244.02% of S&P 500 Index downside but only -105.30% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PHIO ranks 42 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Phio Pharmaceuticals Corp. (PHIO) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Phio Pharmaceuticals Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Phio Pharmaceuticals Corp. was 100.00%, occurring on Feb 5, 2026. The portfolio has not yet recovered.

The current Phio Pharmaceuticals Corp. drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Phio Pharmaceuticals Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Phio Pharmaceuticals Corp. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.